Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cassanello

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
American Journal of Medical Genetics. Part A|June 7, 2008
Peroxisomal acyl-CoA-oxidase deficiency: two new casesRosalba Carrozzo, Carlo Bellini, Simona Lucioli, et al.
Current Pediatric Reviews|January 28, 2022
Adenosine Blood Level: A Biomarker of White Matter Damage in Very Low Birth Weight InfantsMarina Colella, Isabella Panfoli, Matteo Doglio, et al.
American Journal of Hematology|March 15, 2026
Three-Hour Infusion of Methotrexate at 3 g/m<sup>2</sup> With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS RiskAndrés J M Ferreri, Federico Erbella, Piera Angelillo, et al.
Blood Cancer Journal|August 29, 2025
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab eraGiulio Cassanello, Esther Drill, Annie Qiu, et al.
American Journal of Hematology|May 21, 2024
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysisAseel Alsouqi, Gulrayz Ahmed, Juntian Wang, et al.
Blood Advances|October 29, 2024
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomesYannis K Valtis, Sean Devlin, Roni Shouval, et al.
Haematologica|September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experienceGiulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Transplantation and Cellular Therapy|July 7, 2024
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.
Blood Cancer Discovery|December 12, 2024
Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell LymphomaDanny Luan, Susan DeWolf, Teng Fei, et al.
British Journal of Haematology|July 1, 2025
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experienceGiulio Cassanello, Efrat Luttwak, Samantha Brown, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
American Journal of Medical Genetics. Part A|June 7, 2008
Peroxisomal acyl-CoA-oxidase deficiency: two new casesRosalba Carrozzo, Carlo Bellini, Simona Lucioli, et al.
Current Pediatric Reviews|January 28, 2022
Adenosine Blood Level: A Biomarker of White Matter Damage in Very Low Birth Weight InfantsMarina Colella, Isabella Panfoli, Matteo Doglio, et al.
American Journal of Hematology|March 15, 2026
Three-Hour Infusion of Methotrexate at 3 g/m<sup>2</sup> With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS RiskAndrés J M Ferreri, Federico Erbella, Piera Angelillo, et al.
Blood Cancer Journal|August 29, 2025
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab eraGiulio Cassanello, Esther Drill, Annie Qiu, et al.
American Journal of Hematology|May 21, 2024
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysisAseel Alsouqi, Gulrayz Ahmed, Juntian Wang, et al.
Blood Advances|October 29, 2024
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomesYannis K Valtis, Sean Devlin, Roni Shouval, et al.
Haematologica|September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experienceGiulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Transplantation and Cellular Therapy|July 7, 2024
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.
Blood Cancer Discovery|December 12, 2024
Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell LymphomaDanny Luan, Susan DeWolf, Teng Fei, et al.
British Journal of Haematology|July 1, 2025
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experienceGiulio Cassanello, Efrat Luttwak, Samantha Brown, et al.
Pageof 8